Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Down 17.3% in December

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totalling 39,800 shares, a decline of 17.3% from the November 30th total of 48,100 shares. Based on an average daily volume of 338,600 shares, the short-interest ratio is presently 0.1 days. Approximately 2.7% of the company’s stock are short sold.

Phio Pharmaceuticals Trading Down 7.7 %

PHIO stock traded down $0.16 during trading on Friday, reaching $1.93. The stock had a trading volume of 255,504 shares, compared to its average volume of 117,227. Phio Pharmaceuticals has a 1-year low of $1.53 and a 1-year high of $10.35. The firm has a fifty day moving average price of $2.68 and a 200 day moving average price of $3.46. The company has a market capitalization of $2.04 million, a P/E ratio of -0.18 and a beta of 1.49.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.